CHI Logo

Novel Vaccines: Adjuvants & Delivery Systems


Loading...

 

ADJ Header

 

Download Brochure 


Adjuvants and novel delivery systems hold the promise of innovating vaccines by enhancing the immune response, decreasing dosage requirements, and overcoming cold chain challenges. More than just a tool for vaccine developers, Adjuvants have become an integral part of the solution for fighting disease. Lack of FDA approval for new Adjuvants presents a major hurdle for vaccine developers, as do the pressing concerns for undesirable side effects. In the Novel Vaccines’ “Adjuvants & Delivery Systems” meeting, vaccine leaders will discuss their promising work that is leading the way to Next Generation Vaccines.

TOLL-LIKE RECEPTORS


Opening Keynote Presentation:
Cytokines and Toll-Like Receptor Ligands as Adjuvants to Improve the Quality as well as Quantity of T Cell Immune Responses

Jay A. Berzofsky, M.D., Ph.D., Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health


Talk Title to be Announced

Nathalie Garçon, Ph.D., VP & Head, Research & N. American R&D, GlaxoSmithKline Biologicals

Talk Title to be Announced

Sean Tucker, Ph.D., Founder, VP Research & CSO, Vaxart, Inc.

Talk Title to be Announced

Bali Pulendran, Ph.D., Professor, Pathology, Emory University School of Medicine

INNOVATIONS & SAFETY

Adjuvantation of a Vaccine without Adjuvant Injection

Mei X. Wu, M.D., Ph.D., Associate Professor, Wellman Center for Photomedicines, MGH/Harvard Medical School

Clinical Safety of the ISCOMATRIX Adjuvant

Marli Watt, M.D., Clinical Safety Physician, Clinical Safety, CSL Limited


ENHANCING THE IMMUNE RESPONSE

Enhancement of Response to Vaccines with the Use of an Immune Modulating Peptide, Thymosin Alpha 1

Israel Rios, M.D., CMO & Senior VP, SciClone Pharmaceuticals, Inc.

Vaccine Immune-Enhancing Delivery Systems: From Danger Signals to a Nutritive Approach in Vaccine and Adjuvant Design

Michael Vajdy, Ph.D., CEO, EpitoGenesis, Inc.


MODES OF DELIVERY

Mucosal Immunization against Vaginal Candida Infections Using Sap2 Recombinant Protein Delivered by Influenza Virosomes

Rinaldo Zurbriggen, Ph.D., Senior Program Manager, Biopharma Manufacturing, Lonza AG

Intranasal Nanoemulsion Adjuvanted Influenza Vaccine – Dose Range Efficacy and Toxicity Studies

Tarek Hamouda, M.D., Ph.D., M.B.A., Director of Vaccines, NanoBio Corp.


PARTICULATE DELIVERY

How VLPs Develop Their Efficacy

Thomas Stauffer, Ph.D., CEO, Pevion Biotech

Synthetic Virus-Like Particle (SVLP) Technology in Synthetic Vaccine Design

Arin Ghasparian, Ph.D., CSO, Virometix AG

Lecithin Nanoparticles as an Adjuvant for Vaccines

Zhengrong Cui, Ph.D., Associate Professor, College of Pharmacy, The University of Texas at Austin


DNA VACCINES

Heterologous Prime-Boost Vaccines for HIV Vaccine Development

Shan Lu, M.D., Ph.D., Professor, Medicine, University of Massachusetts Medical School

Designing Smarter Adenoviral Vector Delivery of Vaccines: What Has Translated Successfully into Humans

Alfredo Nicosia, Ph.D., CSO, Okairos

SynCon DNA Vaccines for Emerging Infectious Diseases

Niranjan Y. Sardesai, Ph.D., Senior VP, Research & Development, Inovio Biomedical Corporation


By Series:
By Region:

Loading...

2010 Conference
& Course Catalog

CHI Catalog